Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial

Leiter Lawrence A.; Cariou Bertrand; Mueller-Wieland Dirk; Colhoun Helen M.; Del Prato Stefano; Tinahones Francisco J.; Ray Kausik K.; Bujas-Bobanovic Maja; Domenger Catherine; Mandel Jonas; Samuel Rita; Henry Robert R.

首页> 外文期刊>Diabetes, obesity & metabolism >Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial

【24h】

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial

机译：Alirocumab在1型或2型糖尿病和高心血管风险中的Alirocumab在胰岛素治疗的个体中的疗效和安全性：奥德赛DM-insulin随机试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

AimsTo investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or type 1 diabetes (T1D) treated with insulin who have elevated LDL cholesterol levels despite maximally tolerated statin therapy.

机译：Aimsto研究了Alirocumab在参与者中的参与者的疗效和安全性，或者在胰岛素治疗的胰岛素治疗的1型糖尿病（T1D），尽管他汀类药物治疗最大耐受性胆固醇水平升高。

著录项

来源
《Diabetes, obesity & metabolism》 |2017年第12期|共12页
作者
Leiter Lawrence A.; Cariou Bertrand; Mueller-Wieland Dirk; Colhoun Helen M.; Del Prato Stefano; Tinahones Francisco J.; Ray Kausik K.; Bujas-Bobanovic Maja; Domenger Catherine; Mandel Jonas; Samuel Rita; Henry Robert R.;
展开▼
作者单位

Univ Toronto St Michaels Hosp Li Ka Shing Knowledge Inst Toronto ON Canada;

Univ Nantes CNRS INSERM Dept Endocrinol CHU Nantes Inst Thorax Nantes France;

Univ Hosp RWTH Aachen Dept Internal Med 1 Aachen Germany;

Univ Edinburgh Edinburgh Midlothian Scotland;

Univ Pisa Dept Clin &

Expt Med Pisa Italy;

Malaga Univ Hosp Virgen Victoria CIBERobn Malaga Spain;

Imperial Coll London Sch Publ Hlth Dept Primary Care &

Publ Hlth London England;

Sanofi Paris France;

Sanofi Gentilly France;

Sanofi Chilly Mazarin France;

Regeneron Pharmaceut Inc Tarrytown NY 10591 USA;

Univ Calif San Diego Sch Med San Diego CA 92103 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词
cardiovascular disease; clinical trial; lipid-lowering therapy; type 1 diabetes; type 2 diabetes;

机译：心血管疾病;临床试验;降脂治疗;1型糖尿病;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial [J] . Leiter Lawrence A., Cariou Bertrand, Mueller-Wieland Dirk, Diabetes, obesity & metabolism . 2017,第12期

机译：Alirocumab在1型或2型糖尿病和高心血管风险中的Alirocumab在胰岛素治疗的个体中的疗效和安全性：奥德赛DM-insulin随机试验
2. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk [J] . Dirk Müller-Wieland, Lawrence A. Leiter, Bertrand Cariou, Cardiovascular Diabetology . 2017,第1期

机译：ODYSSEY DM-DYSLIPIDEMIA试验的设计和原理：Alirocumab在具有高心血管风险的2型糖尿病和混合性血脂异常患者中的降脂功效和安全性
3. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk [J] . Dirk Müller-Wieland, Lawrence A. Leiter, Bertrand Cariou, Cardiovascular Diabetology . 2017,第1期

机译：ODYSSEY DM-DYSLIPIDEMIA试验的设计和原理：Alirocumab在具有高心血管风险的2型糖尿病和混合性血脂异常患者中的降脂功效和安全性
4. Determining Significant Risk Factors for Cardiovascular Complications of Patient with Type 2 Diabetes Mellitus and Hypertension Using Multi-Expert Multi-Criteria Decision Making [C] . Napa Rachata International Conference on Digital Arts, Media and Technology;ECTI Northern Section Conference on Electrical, Electronics, Computer and Telecommunications Engineering . 2021

机译：使用多专家多标准决策，确定2型糖尿病患者心血管并发症的显着危险因素及高血压
5. Decreasing the confusion of diabetes: Focused education and management risk reduction strategies aimed at decreasing cardiovascular risk for patients with type 2 diabetes. [D] . Kimpton, Shandra Lee Ann. 2003

机译：减少糖尿病的混乱：集中的教育和管理风险降低策略旨在降低2型糖尿病患者的心血管风险。
6. Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial [O] . Lawrence A. Leiter, Bertrand Cariou, Dirk Müller‐Wieland, -1

机译：Alirocumab在接受胰岛素治疗的1型或2型糖尿病和高心血管风险患者中的疗效和安全性：ODYSSEY DM-INSULIN随机试验
7. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial [O] . Leiter, Lawrence A., Cariou, Bertrand, MÃ¼ller-Wieland, Dirk, 2017

机译：Alirocumab在接受胰岛素治疗的1型或2型糖尿病和高心血管风险患者中的疗效和安全性：ODYSSEY DM-INSULIN随机试验

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅